Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.00.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Metagenomi in a report on Monday, December 22nd.

Metagenomi Stock Performance

MGX opened at $1.46 on Monday. The company’s 50-day simple moving average is $1.62 and its two-hundred day simple moving average is $1.95. The stock has a market capitalization of $54.82 million, a P/E ratio of -0.61 and a beta of 0.50. Metagenomi has a 52-week low of $1.23 and a 52-week high of $3.95.

Institutional Trading of Metagenomi

Several large investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC increased its position in Metagenomi by 53.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company’s stock valued at $32,000 after acquiring an additional 7,458 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Metagenomi by 1,840.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock valued at $36,000 after purchasing an additional 14,389 shares during the period. Bank of America Corp DE increased its position in shares of Metagenomi by 508.5% during the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after purchasing an additional 15,682 shares during the last quarter. Panagora Asset Management Inc. bought a new position in shares of Metagenomi in the 4th quarter worth approximately $53,000. Finally, Quadrature Capital Ltd bought a new position in shares of Metagenomi in the 4th quarter worth approximately $55,000.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.